High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• HER2+ breast cancer is an aggressive subtype requiring novel therapeutic strategies.
• Current targeted treatments like trastuzumab and lapatinib improve outcomes but face resistance.
• Identifying effective drug combinations is crucial for overcoming treatment limitations.

Purpose of the Study:

• To identify compounds that enhance the efficacy of trastuzumab and lapatinib in HER2+ breast cancer.
• To evaluate the in vitro and in vivo effects of promising drug combinations.
• To analyze downstream molecular changes induced by these treatments.

Main Methods:

• High-throughput drug screening of 278 compounds combined with lapatinib and trastuzumab.
• Utilized two HER2+ breast cancer cell lines (KPL4, SUM190PT) for screening.
• In vitro and in vivo validation, including xenograft models and protein analysis.
• In silico analysis of molecular pathways.

Main Results:

• Multiple compounds showed synergistic effects with lapatinib and/or trastuzumab.
• Dasatinib, a Src-inhibitor, demonstrated significant combinatorial effects with lapatinib in KPL4 cells (p < 0.01).
• In vivo, only lapatinib significantly reduced tumor growth; dasatinib combinations did not show significant effects, though molecular changes were observed.

Conclusions:

• Dasatinib shows potential for combination therapy in HER2+ breast cancer, warranting further investigation.
• Molecular analyses indicate drug penetration and pathway modulation in vivo.
• Further research is needed to optimize combination strategies for improved clinical outcomes in HER2+ breast cancer.